AstraZeneca (an inexperienced vaccine player) has emerged as top contender in the COVID-19 vaccine race, post its deal with Oxford University. The potential vaccine’s much-lower price and multiple out-licensing deals, resulting in major capacities being secured, have been two critical milestones and, recently, the US President announced plans to fast-track Astra’s vaccine approval before the November 2020 US elections. Interestingly, Astra is also a minority shareholder in Moderna
31 Aug 2020
An assessment of Astra’s COVID-19 vaccine journey
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
An assessment of Astra’s COVID-19 vaccine journey
AstraZeneca PLC (AZN:LON) | 10,689 0 0.0% | Mkt Cap: 165,702m
- Published:
31 Aug 2020 -
Author:
Surbhit Gupta -
Pages:
5
AstraZeneca (an inexperienced vaccine player) has emerged as top contender in the COVID-19 vaccine race, post its deal with Oxford University. The potential vaccine’s much-lower price and multiple out-licensing deals, resulting in major capacities being secured, have been two critical milestones and, recently, the US President announced plans to fast-track Astra’s vaccine approval before the November 2020 US elections. Interestingly, Astra is also a minority shareholder in Moderna